https://scholars.lib.ntu.edu.tw/handle/123456789/568476
標題: | Hepatitis B virus reactivation in patients receiving cancer chemotherapy: Natural history, pathogenesis, and management | 作者: | CHUN-JEN LIU PEI-JER CHEN DING-SHINN CHEN JIA-HORNG KAO |
公開日期: | 2013 | 出版社: | Springer New York LLC | 卷: | 7 | 期: | 2 | 起(迄)頁: | 316-326 | 來源出版物: | Hepatology International | 摘要: | Chronic hepatitis B virus (HBV) infection is endemic in the Asian-Pacific region, and reactivation of HBV post-cancer chemotherapy has become an emerging clinical challenge. Patients with detectable serum HBV DNA before chemotherapy and those receiving intensive chemotherapy are particularly at a risk of HBV reactivation. Most patients with HBV reactivation are positive for hepatitis B surface antigen (HBsAg) and are, therefore, easily identified by recommended serological screening before chemotherapy. However, a small, but significant proportion of subjects who have apparently recovered from HBV infection as reflected by HBsAg negativity and hepatitis B core antibody positivity in HBV endemic areas may also experience reactivation when host immunity is severely compromised by cancer chemotherapy. Serum alanine aminotransferase, HBsAg, and/or HBV DNA should be monitored closely in these subjects and antiviral therapy should be administered immediately when any evidence of HBV reactivation is detected during chemotherapy. The prophylactic use of nucleos(t)ide analogs before chemotherapy and its continuation until reconstitution of host immunity remain the mainstay of effective prevention of hepatitis B reactivation in this special clinical entity. ? 2011 Asian Pacific Association for the Study of the Liver. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84984555373&doi=10.1007%2fs12072-011-9279-6&partnerID=40&md5=306340def72808696d47793b3b29967e https://scholars.lib.ntu.edu.tw/handle/123456789/568476 |
ISSN: | 1936-0533 | DOI: | 10.1007/s12072-011-9279-6 | SDG/關鍵字: | adefovir; alanine aminotransferase; corticosteroid; cyclophosphamide; doxorubicin; entecavir; hepatitis B core antibody; hepatitis B surface antigen; infliximab; lamivudine; nucleoside derivative; prednisolone; rituximab; telbivudine; tenofovir; vincristine; virus DNA; adaptive immunity; alanine aminotransferase blood level; cancer combination chemotherapy; cancer patient; enteritis; hepatitis B; Hepatitis B virus; human; immunopathogenesis; incidence; innate immunity; large cell lymphoma; medical history; organ transplantation; practice guideline; priority journal; review; rheumatic disease; risk factor; serology; virus reactivation; virus replication |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。